Real-world study of anlotinib combined with PD-1 inhibitor in treating advanced non-small cell lung cancer with EGFR mutations
LIU Zan
SUOLANG Qunpei
BAIMA Yangjin
Abstract：Objective To evaluate the efficacy and safety of anlotinib combined with programmed death 1(PD-1)inhibitors in treating advanced non-small cell lung cancer(NSCLC)with sensitive mutations in the epidermal growth factor receptor(EGFR)gene.Methods A total of 278 advanced NSCLC patients who were treated with the combination of anlotinib with PD-1 inhibitors from January 2020 to December 2023 were retrospectively included.Among them,44 patients with EGFR sensitive mutations were enrolled as subjects.Efficacy and safety were analyzed.The correlation between clinical pathological features and progression-free survival(PFS)was identified.PFS curves were constructed using the Kaplan-Meier method.Results Among the 44 patients,the objective response rate(ORR)was 31.8％,and the disease control rate(DCR)achieved 86.3％.Follow-ups were conducted until February 29,2024,showing a median PFS of 7.1 months,and a median overall survival(OS)of 11.7 months.The PFS was significantly correlated with the expression of programmed death ligand 1(PD-L1),type of EGFR mutation,T790M status,history of chemotherapy,and prior use of bevacizumab(P＜0.05).Multivariate analysis indicated that EGFR L858R mutation(odds ratio[OR]=2.604,P=0.012),non-use of bevacizumab(OR=2.594,P=0.004),and T790M-negative status(OR=2.575,P=0.010)were significantly correlated with the prolonged median PFS.A total of 6 patients experienced grade 3 or higher adverse events.Conclusion The combination of anlotinib and PD-1 inhibitors demonstrates promising therapeutic efficacy in advanced NSCLC patients carrying EGFR-sensitive mutations who are resistant to EGFR-tyrosine kinase inhibitor(TKI)therapy,with particularly favorable outcomes observed in patients harboring the EGFR L858R mutation,those who have not received bevacizumab,and those with a T790M-negative status.
Keywords：anlotinibEGFR mutationnon-small cell lung cancerPD-1 inhibitor
Publication Date：2025-12-26
Online Publishing Date：2026-01-15(First online date of this platform, not the publication date of the document)
Pages：6( 1967-1972 )